Jason T. Huse

The University of Texas MD Anderson Cancer Center

Full Professor(heuristic)

Glioma Diagnosis and Treatment · Genetics

h-index90

i10-index198

Publications661

Citations45,259

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 93

Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation
Nature Genetics · 2026-06-22
Figure S1 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S7 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S4 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S8 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S5 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Supplementary Table 1 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S3 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Supplementary Table 5 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S2 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Supplementary Table 3 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Supplementary Table 2 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S6 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Figure S9 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
Supplementary Table 4 from Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer
2026-06-17
ATRX inactivation disrupts global chromatin state and topology to dysregulate neurodevelopmental pathways in glioma pathogenesis
Nucleic Acids Research · 2026-06-16
Single cell spatial profiling of the matrisome identifies region-specific adhesion and signaling networks in glioblastoma
Communications Biology · 2025-12-09 · 2 citations
ATRX Loss Predicts Poor Outcomes and Reveals a Therapeutic Vulnerability to TEAD Inhibition in Soft Tissue SarcomasPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-26
A network-based discovery of prognostic markers in recurrent IDH wild-type gliomas
Frontiers in Genetics · 2025-11-20
Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma
Advanced Science · 2025-11-14 · 2 citations

Open author page on OpenAlex →